上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Erythromycin thiocyanate (Synonyms: 红霉素硫氰酸盐)
Erythromycin thiocyanate 是由放线菌产生的大环内酯类抗生素 (antibiotic),具有广泛的抗菌活性。Erythromycin thiocyanate 通过结合细菌的 50S 核糖体亚基而起作用,并通过阻断转肽和/或易位反应来抑制 RNA 依赖性蛋白 (RNA-dependent protein synthesis) 的合成,而不会影响核酸的合成。Erythromycin thiocyanate 在不同领域的研究中显示出抗肿瘤特性和保护神经的作用。
Erythromycin thiocyanate Chemical Structure
CAS No. : 7704-67-8
规格 |
|
是否有货 |
|
100 mg |
|
询价 |
|
250 mg |
|
询价 |
|
500 mg |
|
询价 |
|
* Please select Quantity before adding items.
Erythromycin thiocyanate 的其他形式现货产品:
Erythromycin
生物活性 |
Erythromycin thiocyanate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin thiocyanate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin thiocyanate also exhibits antitumor and neuroprotective effect in different fields of research[3][4].
|
IC50 & Target |
Bacterial; RNA-dependent protein synthesis[1]
|
体外研究 (In Vitro) |
Erythromycin thiocyanate inhibits growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[1]. Erythromycin thiocyanate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly[4].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[4]
Cell Line: |
Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat) |
Concentration: |
10, 100 μM |
Incubation Time: |
24, 72 hours |
Result: |
Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD). |
|
体内研究 (In Vivo) |
Erythromycin thiocyanate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice[3]. Erythromycin thiocyanate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg[3]. Erythromycin thiocyanate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury[4].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Female ddY mice (6-week-old) with EAC cells or CDF mice (6-week-old) with P388 cells[3] |
Dosage: |
0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg |
Administration: |
Gastric intubation; 30-120 days |
Result: |
Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice. |
Animal Model: |
Male Sprague-Dawley rats (8-week-old, 250-300 g)[4] |
Dosage: |
50 mg/kg |
Administration: |
Subcutaneous single injection |
Result: |
Reduced infarct volume and edema volume, improved neurological deficit. |
|
Clinical Trial |
|
分子量 |
|
Formula |
|
CAS 号 |
|
中文名称 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
参考文献 |
-
[1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.
[2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28.
[3]. Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69.
[4]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67.
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务